Web: Novartis external link
Lieu: Bâle
Domaine: Médecine/Pharmacologie
Lié à:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.

Médecine 9.12
Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozole MONALEESA-2 analyses demonstrate superior PFS with LEE011 plus letrozole in pre-defined patient subgroups - from de novo to bone, liver and lung metastases - compared to letrozol
Médecine 8.12

Ultibro Breezhaler improved lung function and breathlessness after direct switch from long-acting bronchodilators or steroid-containing combination therapies -   Results further support the 2017 GO

Médecine 6.12

Patients without brain metastases at diagnosis experienced median progression-free survival of 26.3 months, the longest seen in a global Phase III study in ALK+ NSCLC -   Patients with measurab

Médecine 5.12

Findings across six countries and four continents showed a reduction in quality of life for majority (71%) of patients living with myeloproliferative neoplasms (MPNs)   -   Patients reported a dimi

Médecine 7.12

Novartis' Lucentis received EU approval in new indication - Lucentis the only treatment available for a wide range of CNV conditions The European Commission approved Lucentis to treat patients for

Médecine 5.12

ASSIST-FL trial demonstrates equivalent safety, efficacy, pharmacokinetics and pharmacodynamics of Sandoz proposed biosimilar rituximab (GP2013) to the reference product Interim data in over 600 ad

Médecine 5.12

ENESTop post-hoc analysis provides further insights into Treatment-free Remission (TFR) among Ph+ CML switch patients The Tasigna TFR trials, including ENESTop, demonstrate our continued commitment


Medicine and Life Sciences